Which clinical and laboratory parameters should be monitored during anti‑tuberculosis therapy?

Monitoring During Anti-TB Treatment

All patients on anti-TB treatment require baseline liver function tests, with subsequent monitoring based on risk stratification—patients with normal baseline liver function and no risk factors need only clinical monitoring with symptom education, while high-risk patients require intensive biochemical surveillance (weekly for 2 weeks, then biweekly for 2 months). 1

Pre-Treatment Baseline Assessment

Before starting anti-TB therapy, establish baseline parameters:

• Visual acuity (Snellen chart) if ethambutol will be used 1
• Renal function if streptomycin or ethambutol will be prescribed 1
• Liver function tests (AST/ALT, bilirubin) for all clinical TB cases 1

Risk-Stratified Monitoring Approach

Low-Risk Patients (Clinical Monitoring Only)

For patients with normal pre-treatment liver function and no risk factors, routine biochemical monitoring is not required 1. Instead:

• Educate patients about hepatotoxicity symptoms (fever, malaise, vomiting, jaundice, unexplained deterioration)
• Instruct patients to stop medications immediately and seek medical evaluation if symptoms develop
• Inform the general practitioner of this protocol
• Repeat liver function tests only if symptoms occur 1

High-Risk Patients (Intensive Biochemical Monitoring)

Weekly liver function tests for 2 weeks, then biweekly for the first 2 months are required for patients with: 1

• Known chronic liver disease (alcoholism, chronic active hepatitis, cirrhosis)
• Hepatitis B or C antigen positive status
• HIV infection 2
• Pregnancy or within 3 months postpartum 2
• Age ≥35 years (consider on individual basis) 2
• Regular alcohol use 2
• Concurrent hepatotoxic medications 2

Managing Elevated Transaminases

If AST/ALT is <2× upper limit of normal:

• Repeat at 2 weeks
• If falling: monitor only for symptoms
• If rising above 2× normal: escalate to weekly monitoring 1

If AST/ALT is 2-5× upper limit of normal:

• Monitor weekly for 2 weeks, then biweekly until normalized 1

If AST/ALT ≥5× normal OR bilirubin elevated:

• Stop rifampicin, isoniazid, and pyrazinamide immediately 1
• For non-infectious TB in stable patients: withhold treatment until liver function normalizes
• For infectious TB or unwell patients: use streptomycin and ethambutol with appropriate monitoring 1

Drug-Specific Monitoring

Ethambutol

• Baseline visual acuity (Snellen chart) mandatory 1
• Patient must be able to report visual symptoms
• Document patient education to stop drug immediately if visual changes occur
• For children or those with language barriers: educate family members 1
• Stop immediately if any deterioration in visual fields or color vision 3

Injectable Agents (Streptomycin, Kanamycin, Amikacin, Capreomycin)

• Baseline audiometry (pure tone audiometry or otoacoustic emissions) 3
• Renal function monitoring (creatinine, potassium) 1, 3
• If hearing loss detected: strong consideration to stop/switch the injectable 3
• Markedly elevated creatinine or potassium: cease all nephrotoxic drugs 3

Ethionamide/Prothionamide

• Thyroid function (T4) monitoring 3
• If T4 low: continue medications and supplement with 0.05 mg thyroxine daily
• Monitor and increase to 0.1 mg daily if needed 3

Linezolid (for drug-resistant TB)

• Monitor for peripheral neuropathy clinically 3
• Increase pyridoxine dose or reduce linezolid dose for mild symptoms
• Stop drug if severe or persistent despite intervention 3

Treatment Response Monitoring

Bacteriological Monitoring

• Sputum smears and cultures should become negative by 3 months 4
• Reevaluate immediately if smear-positive at 3 months for:
  • Non-adherence (most common cause)
  • Drug-resistant bacilli 4
• Obtain specimens for culture and drug susceptibility testing
• Never add a single drug to a failing regimen—add ≥2 drugs to prevent resistance 4

Clinical Assessment Frequency

For standard regimens (isoniazid/rifampin-based):

• Monthly clinical evaluations minimum 2

For rifampin-pyrazinamide regimens (if used):

• In-person assessment at 2,4,6, and 8 weeks 5
• Measure serum aminotransferases and bilirubin at each visit 5
• Dispense only 2-week supplies 5

For BPaLM regimens (bedaquiline/pretomanid/linezolid/moxifloxacin):

• Baseline, monthly, and as-needed clinical, radiologic, and laboratory assessments 6
• Increase frequency for older patients, HIV-positive, diabetes, baseline anemia, visual impairment, renal/liver disease 6

Critical Pitfalls to Avoid

1. Do not continue treatment for ≥10 days after hepatotoxicity symptoms appear—this is associated with fulminant hepatic failure requiring transplantation 2

2. Do not perform routine biochemical monitoring in low-risk patients—this wastes resources without improving outcomes; clinical monitoring is sufficient 1

3. Do not use ethambutol without baseline visual acuity testing—you cannot monitor for toxicity without a baseline 1

4. Do not add single drugs to failing regimens—this creates de facto monotherapy and amplifies resistance 4

5. Do not delay renal function checks when using aminoglycosides—nephrotoxicity can be irreversible 1

Post-Treatment Surveillance

Monitor for at least 1-2 years post-treatment to identify recurrence 6